Valuation: Ipsen

Market Cap 11.94B 13.28B 11.14B 10.1B 18.96B 1,264B 19.07B 134B 52.2B 656B 49.85B 48.77B 2,109B P/E 2026 *
12.1x
P/E 2027 * 12x
Enterprise Value 10.68B 11.88B 9.97B 9.03B 16.96B 1,130B 17.07B 120B 46.71B 587B 44.6B 43.63B 1,887B EV / Sales 2026 *
2.33x
EV / Sales 2027 * 2.08x
Free-Float
40.65%
Yield 2026 *
1.05%
Yield 2027 * 1.07%
1 day+2.10%
1 week+0.41%
Current month+2.46%
1 month-8.49%
3 months-8.08%
6 months-11.76%
Current year+22.35%
1 week 141.6
Extreme 141.6
145.8
1 month 138.3
Extreme 138.3
160.7
Current year 116
Extreme 116
174
1 year 112.7
Extreme 112.7
174
3 years 87.95
Extreme 87.95
174
5 years 77
Extreme 77
174
10 years 34.2
Extreme 34.2
174
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Date Insider Type Main position Quantity % Market Cap. Importance
21/9/26 Buy

Director

500 0.0006%
8/9/26 Buy

Director

500 0.0006%
3/9/26 Sell

Director

-1,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+2.10%+0.41%+27.94%+22.46% 13.09B
+3.62%+1.68%+48.80%+98.41% 1,040B
+2.13%-1.76%+33.04%+61.88% 599B
+3.32%+4.47%+23.72%+91.59% 485B
+3.80%+3.21%+73.99%+41.69% 350B
+3.09%+3.03%+29.59%+45.42% 345B
+2.82%+2.20%+17.90%+40.15% 272B
+3.40%+0.99%-3.44%+12.08% 244B
+3.21%+3.15%+45.01%+49.99% 223B
+3.80%+4.56%+29.59%+97.73% 183B
Average +2.93%+1.75%+32.61%+56.14% 375.59B
Weighted average by Cap. +2.66%+1.53%+36.75%+68.52%

Financials

2026 *2027 *
Net sales 4.59B 5.1B 4.28B 3.88B 7.28B 485B 7.33B 51.36B 20.06B 252B 19.15B 18.74B 810B 4.72B 5.24B 4.4B 3.99B 7.49B 499B 7.53B 52.81B 20.62B 259B 19.69B 19.26B 833B
Net income 1.01B 1.12B 941M 853M 1.6B 107B 1.61B 11.29B 4.41B 55.4B 4.21B 4.12B 178B 1.02B 1.14B 955M 866M 1.63B 108B 1.64B 11.46B 4.48B 56.23B 4.27B 4.18B 181B
Net Debt -1.26B -1.4B -1.17B -1.06B -2B -133B -2.01B -14.08B -5.5B -69.06B -5.25B -5.14B -222B -2.15B -2.39B -2B -1.82B -3.41B -227B -3.43B -24.05B -9.39B -118B -8.97B -8.77B -379B
Projected Income Statement - Annual - Ipsen
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
14/10/26 EUR 145.60 +2.10% 163,923
13/10/26 EUR 142.60 -1.04% 99,154
12/10/26 EUR 144.10 +0.98% 76,047
09/10/26 EUR 142.70 +0.85% 63,464
08/10/26 EUR 141.50 -2.41% 115,985
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Ipsen
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
145.60EUR
Average target price
164.29EUR
Spread / Average Target
+12.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipsen